VLP platform

An innovation Platform for Next-Generation Vaccine
Development to Overcome Future Pandemics

Virus-Like Particle (VLP) Vaccine

Maintains antigenicity equivalent to native viral antigens.

No risk of pathogenicity reversion from virus-based platforms.

Compatible with various production methods, including cell culture systems.

Does not require expensive high-level biosafety facilities.

Shorter production timelines compared to traditional vaccine manufacturing methods.

Significantly reduces production costs depending on the chosen production method.

Comparison of Virus-Like Particle (VLP) Vaccines and Traditional Vaccines

VLP(Virus Like Particle) Vaccine

A recombinant protein-based vaccine composed of particles that replicate the viral envelope without containing viral genetic material.

  • 1 What is VLP(Virus-Like Particle) technology?

    Virus-Like Particle (VLP) technology is an innovative biotechnology that mimics the structure of a virus without being infectious. Due to this characteristic, it offers enhanced safety with minimal side effects while effectively inducing a strong immune response.

  • 2 Principles of VLP (Virus-Like Particle) Technology

    VLPs (Virus-Like Particles) resemble the structure of viruses but lack the genetic material required to cause infection. When introduced into the body, VLPs are recognized as viruses by the immune system, triggering an immune response and promoting the formation of antibodies. This enables rapid and strong protection in the event of actual viral infection. Our VLP technology is optimized for high-efficiency production across various platforms, and is designed to induce a safer and more effective immune response compared to conventional vaccines and therapeutics.

  • 3 Advantages of VLP (Virus-Like Particle) Technology

    No Risk of Infection : VLPs do not contain viral genetic material, eliminating any risk of replication or infection.

    High Immunogenicity : They trigger strong immune responses by activating innate immunity, often without the need for additional adjuvants, and help build long-lasting immune memory.

    Scalable Production : VLPs can be mass-produced using E. coli expression systems, enabling cost-effective manufacturing at scale.

  • 4 EAVE (Enhanced-Assembly VLP Expression)

    Multi-vector Combined Co-expression System

    Protein Expression Trigger Factor Competent Cells

    Optimized Culture Conditions in Autoinduction System

    Multi-antigen Co-expression System